<?xml-stylesheet type="text/css" href="C:\Users\Fernando\Documents\CIPF\Pharm Pract\Pubmed Central\JATS_OXYGEN\jats.css"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharm Pract (Granada)</journal-id><journal-id journal-id-type="iso-abbrev">Pharm Pract (Granada)</journal-id><journal-id journal-id-type="publisher-id">Pharm Pract</journal-id><journal-title-group><journal-title>Pharmacy Practice</journal-title></journal-title-group><issn pub-type="ppub">1885-642X</issn><issn pub-type="epub">1886-3655</issn><publisher><publisher-name>Centro de Investigaciones y Publicaciones Farmaceuticas</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26131047</article-id><article-id pub-id-type="pmc">4482847</article-id><article-id pub-id-type="publisher-id">PhP-575</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>A pharmacist-led follow-up program for patients with established coronary heart disease in North Norway &#x02013; a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>Beate H.</given-names></name><aff>Hospital Pharmacy of North Norway; &#x00026; Department of Pharmacy, <institution>University of Troms&#x000f8;</institution>. Troms&#x000f8; (<country>Norway</country>). <email xlink:href="beate.garcia@uit.no">beate.garcia@uit.no</email></aff></contrib><contrib contrib-type="author"><name><surname>Giverhaug</surname><given-names>Trude</given-names></name><aff>Regional Drug Information Center of North Norway &#x00026; University Hospital of North-Norway.
Troms&#x000f8; (<country>Norway</country>). <email xlink:href="trude.giverhaug@unn.no">trude.giverhaug@unn.no</email></aff></contrib><contrib contrib-type="author"><name><surname>H&#x000f8;gli</surname><given-names>June U.</given-names></name><aff>Department of Pharmacy, <institution>University of Troms&#x000f8;</institution>. Troms&#x000f8; (<country>Norway</country>). <email xlink:href="june.utnes@uit.no">june.utnes@uit.no</email></aff></contrib><contrib contrib-type="author"><name><surname>Skjold</surname><given-names>Frode</given-names></name><aff>Department of Pharmacy, <institution>University of Troms&#x000f8;</institution>, Troms&#x000f8; (<country>Norway</country>). <email xlink:href="frode.skjold@uit.no">frode.skjold@uit.no</email></aff></contrib><contrib contrib-type="author"><name><surname>Sm&#x000e5;brekke</surname><given-names>Lars</given-names></name><aff>Department of Pharmacy, <institution>University of Troms&#x000f8;</institution>. Troms&#x000f8; (<country>Norway</country>). <email xlink:href="lars.smabrekke@uit.no">lars.smabrekke@uit.no</email></aff></contrib></contrib-group><pub-date pub-type="ppub" iso-8601-date="20130331"><season>Apr-Jun</season><year iso-8601-date="2012">2015</year></pub-date><pub-date pub-type="epub" iso-8601-date="20130328"><day>15</day><month>6</month><year iso-8601-date="2012">2015</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>575</elocation-id><history><date date-type="received"><day>17</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>07</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pharmacy Practice</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec sec-type="objectives"><title>Objectives:</title><p>The aim of the study was twofold; 1) to develop a clinical pharmacist-led 12 month lasting follow-up program for patients with established coronary heart disease (CHD) discharged from the University Hospital of North Norway, and 2) to explore the impact of the program with regards to adherence to a medication assessment tool for secondary prevention of CHD and change in biomedical risk factors.</p></sec><sec sec-type="methods"><title>Methods:</title><p>A total of 102 patients aged 18-82 years were enrolled in a non-blinded randomized controlled trial with an intervention group and a control group. The intervention comprised medication reconciliation, medication review and patient education during three meetings; at discharge, after three months and after twelve months. The control group received standard care from their general practitioner. Primary outcomes were adherence to clinical guideline recommendations concerning prescription, therapy goal achievement and lifestyle education defined in the medication assessment tool for secondary prevention of CHD (MAT-CHDSP). Secondary outcomes included changes in the biomedical risk factors cholesterol, blood pressure and blood glucose.</p></sec><sec sec-type="results"><title>Results:</title><p>Ninety-four patients completed the trial, 48 intervention group patients and 46 controls. Appropriate prescribing was high, but therapy goal achievement was low in both groups. Overall adherence to MAT-CHDSP criteria increased in both groups and was significantly higher in the intervention group at study end, 78.4% vs. 62.0%, p&#x0003c;0.001. The difference was statistically significant for the documented lifestyle advices in intervention group patients. No significant improvements in biomedical risk factors were observed in favor of the intervention group.</p></sec><sec sec-type="conclusionsb"><title>Conclusions:</title><p>The study showed an increased guideline adherence in both study groups. This indicates that attention to clinical practice guideline recommendations in itself increases adherence &#x02013; which may be a clinical pharmacist task. A larger adequately powered study is needed to show a significant difference in biomedical risk factor improvements in favor of the intervention.</p><p>Amendments to the follow-up program are suggested before implementation in standard patient care can be recommended.</p></sec></abstract><kwd-group kwd-group-type="MESH"><kwd>Pharmaceutical Services</kwd><kwd>Medication Reconciliation</kwd><kwd>Pharmacists</kwd><kwd>Coronary Disease</kwd><kwd>Randomized Controlled Trials as Topic</kwd><kwd>Norway</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>INTRODUCTION</title><p>Coronary heart disease (CHD) is the leading cause of death world-wide, and the major biomedical
risk factors being high blood pressure (BP), high blood cholesterol, smoking, unhealthy diet,
physical inactivity, diabetes, advancing age and genetic disposition.<xref rid="B1" ref-type="bibr">1</xref> Death rates due to CHD are decreasing in most developed countries, but are still a major
public health concern.<xref rid="B2" ref-type="bibr">2</xref> Clinical practice guidelines are
cornerstones for quality improvement, and are constantly developed to support clinicians, health
personnel and patients regarding choice of therapy and monitoring.<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref> Adherence
to clinical practice guidelines has been shown to reduce morbidity, mortality and overall treatment
costs in patients with CHD.<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref> Still, non-adherence to guidelines and achievement of therapeutic goals are inadequate in
this patient group.<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref></p><p>Pharmaceutical care programs developed and implemented by clinical pharmacists have improved the quality of care in both ambulatory care and hospitalized patients with various chronic diseases.<xref rid="B11" ref-type="bibr">11</xref> Considering the substantial body of literature showing benefits of pharmacist involvement in managing risk factors related to CHD, pharmacist-led follow-up programs of this patient group are scarce. The best described programs are developed in the United States and the United Kingdom<xref rid="B12" ref-type="bibr">12</xref>-<xref rid="B14" ref-type="bibr">14</xref>, where pharmacists have been recognized as health care practitioners since the 1990s.<xref rid="B15" ref-type="bibr">15</xref> The largest European program within secondary prevention of CHD (CHDSP), the nurse-coordinated, multidisciplinary, EuroAction program, was initiated in 2002 by the European Society of Cardiology as a reaction to alarming results of large European surveys on CHDSP.<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref> EuroAction has focused upon prescribing of appropriate drugs, achievement of therapy goals, and changes in lifestyle behavior. Results from nine European countries indicate that the program has a significant effect on lifestyle changes, waist circumference, systolic and diastolic BP, and fasting blood glucose.</p><p>In previous studies, we have identified a significant potential for improvement in patients with established CHD discharged from our hospital, especially regarding achievement of therapy goals, follow-up on unachieved therapy goals and documentation of lifestyle recommendations.<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref> The aim of the present study was to design a pharmacist-led follow-up program, and to explore its influences on adherence to clinical practice guidelines as well as changes in biomedical risk factors relevant for CHDSP.</p></sec><sec sec-type="methods" id="S2"><title>METHODS</title><sec id="S3"><title>Study design</title><p>The study was a non-blinded, randomized controlled trial with an intervention group (IG) and a control group (CG). The study site was the University Hospital of North Norway (UNN), a 650-bed teaching hospital. UNN is the leading health care provider in the area of North Norway, and serves about 465,000 inhabitants with respect of procedures like percutaneous coronary interventions and coronary bypass.<xref rid="B20" ref-type="bibr">20</xref></p></sec><sec id="S4"><title>Study subjects, enrolment and randomization</title><p>Patients were recruited from the cardiology ward at UNN during 205 days in the period February 1, 2009 to June 30, 2010 (18 months). Only patients with established CHD were eligible for inclusion. This was defined by a diagnosis of present or previous myocardial infarction, angina pectoris, coronary stent implantation or bypass operation, ascertained by International Statistical Classification of Diseases and Related Health Problems (ICD) code in medical records. Other inclusion criteria included: age 18 to 80 years, self-administration of medications at home, and registered home address within one of the three closest communities to the hospital, i.e. Troms&#x000f8;, Balsfjord and Karlsoey. Patients were excluded if they were already included in another ongoing clinical studies at the ward<xref rid="B21" ref-type="bibr">21</xref>, if they had terminal cancer or if they already received pharmaceutical care at the heart-failure clinic.</p><p>The clinical pharmacist working at the ward identified eligible patients every morning by reviewing patient lists when it was present at the ward. She then informed the patients about the study and invited them to participate. Patients were allocated to intervention group (IG) or control group (CG) in a 1:1 relationship applying an online randomization procedure, stratifying on gender.<xref rid="B22" ref-type="bibr">22</xref> We informed patients instantly about randomization results, as they were going to meet the clinical pharmacist at hospital discharge.</p></sec><sec id="S5"><title>Sample size</title><p>Sample size calculation was based on results from our pilot study revealing that 22% of patients discharged from UNN after elective PCI had achieved a blood pressure (BP) lower than 130/80 mmHg.<xref rid="B18" ref-type="bibr">18</xref> This particular guideline recommendation was chosen due to its low adherence and consequently its improvement potential. A 80% power to detect an increase in BP goal achievement from 20% to 40% in IG patients only, required a sample size of 101 patients in each group, assuming 10% loss.</p></sec><sec id="S6"><title>Standard care</title><p>Patients allocated to the CG received standard care from the hospital and general practitioners (GPs). If patients experience a cardiac event (MI, bypass, PCI) for the first time, the hospital physician refers them to the hospital for follow-up approximately three months after the event. For some patients replaced by a two-day patient-school for CHD including physiotherapy, training, consultation with cardiologist, and lectures about CHD disease, CHD medications, lifestyle modifications and secondary prevention. It is a GP task to follow-up effect and safety of medications in addition to monitoring the disease. Patients experiencing an MI for the second, third time or more may be followed by their GP only, if no complications occur. No one provide standardized pharmaceutical care to any of these patients.</p></sec><sec id="S7"><title>The clinical pharmacist intervention (the follow-up program)</title><p>In addition to standard care, patients allocated to the IG received follow-up from the clinical pharmacist at three points of time: 1) at hospital discharge, 2) three months after hospital discharge and 3) twelve months after discharge. The first meeting was held at the ward, the latter at the hospital pharmacy. The clinical pharmacist arranged follow-up meetings by phone approximately two weeks before due date. The Pharmacist and patient tasks during follow-up meetings are described in <xref ref-type="fig" rid="F1">Figure 1</xref>. Briefly, the follow-up comprised traditional medication reconciliation, clinical medication therapy reviews, and patient education concerning medications, lifestyle behaviour and risk reduction. The latter was performed in the spirit of motivational interviewing, which is described as collaborative, evocative and honouring of patient autonomy.<xref rid="B23" ref-type="bibr">23</xref> There was no strict protocol for these tasks, but the clinical pharmacist used hospital records to prepare for meetings. The pharmacist did not have the authority to make dose adjustments or other medication amendments, but recommendations were communicated to, and/or discussed with, the patients&#x02019; GPs and the patients themselves, both by phone and by letter.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Pharmacist and patient tasks during meetings in the follow-up program for patients with established coronary heart disease led by a clinical pharmacist. Meetings were held at discharge, 3 months post-discharge and 12 months post discharge.</p><p>GP, general practitioner; HbA1c, glycated hemoglobin; LDL, Low-density lipoprotein.</p><p>
<list list-type="simple"><list-item><label>1)</label><p>A calibrated GE Dinamap Pro 300 Patient Monitor and the correct sized cuff were utilized. A standardized three-time measurement procedure was where the average blood pressure was denoted and used for clinical evaluation.</p></list-item><list-item><label>2)</label><p>Discussion/information on diet and preparation of food, exercise advices. When patients wanted to stop smoking, they were much encouraged and were referred to the Norwegian&#x02019;s authorities smoking cessation programs found at the webpage <email xlink:href="www.slutta.no">www.slutta.no</email> or to the &#x02019;smoking telephone&#x02019; (a free phone-line where you meet professional personnel advising you on smoking cessation). When appropriate, the CP suggested choices of food and preparation of food and exercise. On request, or when needed, the CP printed lifestyle recommendations from the webpage of the Norwegian heart association and Norwegian diabetes association and handed out to patients (<email xlink:href="www.hjerte.no">www.hjerte.no</email> or <email xlink:href="www.diabetes.no">www.diabetes.no</email>)</p></list-item><list-item><label>3)</label><p>Published by the National Association for Heart and Lung Diseases (LHL). The folder includes information concerning heart disease, the most normal clinical procedures in relation to CHD, the most common drugs and lifestyle recommendations. Only handed out at the first meeting.</p></list-item></list>
</p></caption><graphic xlink:href="pharmpract-13-575-g001"/></fig></sec><sec id="S8"><title>Data collection</title><p>The following data was collected from predefined electronic patient records: demographics, family history of CHD, medical history relevant for CHD, medication at hospital admission and discharge, systolic and diastolic BP at admission and discharge, serum total cholesterol, serum low-density lipoprotein (LDL) cholesterol, blood glucose, glycated hemoglobin (HbA1c), body weight, height, waist circumference, body mass index (BMI), and any documented instructions concerning medications, life-style and/or follow-up issues given to patients during hospitalization and/or submitted to the next health care level.</p><p>Before each follow-up meeting with the clinical pharmacist, blood samples for analysis of serum total and LDL cholesterol, blood glucose and HbA1c were drawn at the hospital ambulatory facilities. Sampling and analyzing methods were equal to those used for hospitalized patients at UNN. BP was by protocol measured by the clinical pharmacist, trained by a nurse, using standardized equipment.<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref> Twelve months after inclusion, we summoned CG patients for follow-up meetings in order to collect the same laboratory and BP data as IG patients. After data collection and medication reconciliation to verify medication list, medication therapy reviews and patient education was supplied also to CG patients. Information regarding the life-style criteria was based on what occurred during follow-up (documented by the pharmacist), information in electronic patient records, and information from patients themselves.</p></sec></sec><sec id="S9"><title>The MAT-CHDSP</title><p>The MAT-CHDSP is a medication assessment tool (MAT) based on clinical therapy guidelines issued by the European Society of Cardiology. It comprises 21 review criteria related to appropriate prescribing, therapy goal achievement and life-style advices in CHDSP.<xref rid="B18" ref-type="bibr">18</xref> A review criterion can be answered YES (adherence) or NO (non-adherence) according to whether the conditions defined by the standard are met or not. One of the strengths with the MAT methodology is the acknowledgement of justified reasons for non-adherence, which is applied &#x02019;justified non-adherence&#x02019; (NOj) in cases where this is documented. Adherence to MAT criteria is calculated as the number of criteria where the standard can be answered YES divided by the number of applicable criteria, i.e. where the standard is answered YES, NO, NOj or where information is insufficient to answer the standard (IDs). Face and content validity of the MAT-CHDSP, together with its reliability and feasibility, have been shown excellent.<xref rid="B18" ref-type="bibr">18</xref></p><sec id="S10"><title>Outcome measures</title><p>The primary outcome was adherence to the MATCHDSP criteria, both overall (all criteria together) and single criteria. Criterion 6 was omitted because it was outdated. Criterion 14 was omitted because data could not be found in patient records at hospital. Secondary outcomes comprised the biomedical risk factors; total and LDL cholesterol, BP, blood glucose and HbA1c.</p></sec><sec id="S11"><title>Reliability measures</title><p>We explored the reliability of MAT-CHDSP applications by Cohen&#x02019;s Kappa statistics, expressing agreement between two observers. A kappa-value 0.75 or greater was considered excellent agreement.<xref rid="B26" ref-type="bibr">26</xref> The second observer (also a pharmacist) applied the MAT-CHDSP criteria at 12 months, using the clinical pharmacist&#x02019;s patient profiles as information source. The profiles comprised information on medications (after medication reconciliation), medical history, biomedical measure and documentation of lifestyle advices. The clinical pharmacist&#x02019;s personal notes were excluded. The second observer was blinded to study group allocation.</p></sec><sec id="S12"><title>Data analysis</title><p>We managed and analysed data using Microsoft&#x000ae; Office Excel 2002 and SPSS&#x000ae; 16.0 for Windows. PASS&#x000ae; was used for sample size calculations. Continuous variables are expressed as mean with standard deviation (SD) and categorical variables as percentages. Two-sample comparisons were conducted using the Student&#x02019;s t-test for continuous normally distributed variables and the Paired sample t-test for continuous variables within the same group. Comparisons of proportions were carried out using the Pearson chi-square or Fisher&#x02019;s exact test, as appropriate. To test for differences in the change of adherence from baseline to study end in the two groups, we used Normal approximation to the binomial distribution. We used the individual sample t-test to compare the difference in mean change from baseline to 12 months in biomedical values between the study groups. A two-sided p-value of &#x0003c;0.05 was considered statistically significant.</p></sec><sec id="S13"><title>Ethical considerations</title><p>The Regional Committee for Medical Research Ethics (REK) North Norway approved the study on January 8, 2009. All included patients supplied written and informed consent. The study is registered at <email xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</email> (study number NCT01115608).</p></sec></sec><sec sec-type="results" id="S14"><title>RESULTS</title><sec id="S15"><title>Study participants</title><p>About half of the eligible patients did not want to participate. Inclusion was stopped before the estimated sample size was achieved, because of the predefined enrolment period. Finally, 102 patients were recruited, and 51 were randomized to each study group. Eight patients (7.8%) were lost to follow-up, see <xref ref-type="fig" rid="F2">Figure 2</xref>. A total of 48 IG patients and 46 CG patients were subjected for analysis. The study groups did not differ significantly, see <xref ref-type="table" rid="T1">Table 1</xref>.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Patient flow during the randomized controlled trial</p><p>*Patient were assessed for eligibility during 205 days.</p></caption><graphic xlink:href="pharmpract-13-575-g002"/></fig><table-wrap orientation="portrait" id="T1" position="float"><label>Table 1.</label><caption><p>Patient characteristics for the intervention group (n = 48) and the control group (n = 46)</p></caption><table frame="hsides" rules="groups" cellpadding="table" border="1" cellspacing="0" width="400pt"><thead><tr><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Intervention group</th><th align="center" rowspan="1" colspan="1">Control group</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">35 (72)</td><td align="center" rowspan="1" colspan="1">33 (72)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">63.9 (9.0)</td><td align="center" rowspan="1" colspan="1">63.4 (9.9)</td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max values</td><td align="center" rowspan="1" colspan="1">46, 81</td><td align="center" rowspan="1" colspan="1">44, 82</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> (n=44)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">28.6 (6.2)</td><td align="center" rowspan="1" colspan="1">28.9 (4.8)</td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max values</td><td align="center" rowspan="1" colspan="1">20, 54</td><td align="center" rowspan="1" colspan="1">22, 48</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking status, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Yes, no.</td><td align="center" rowspan="1" colspan="1">7 (15)</td><td align="center" rowspan="1" colspan="1">11 (24)</td></tr><tr><td align="right" rowspan="1" colspan="1">Ex, no.</td><td align="center" rowspan="1" colspan="1">16 (33)</td><td align="center" rowspan="1" colspan="1">12 (26)</td></tr><tr><td align="right" rowspan="1" colspan="1">Never, no.</td><td align="center" rowspan="1" colspan="1">24 (50)</td><td align="center" rowspan="1" colspan="1">21 (46)</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidities, no (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Congestive Heart failure (EF&#x0003c;45%)</td><td align="center" rowspan="1" colspan="1">12 (25)</td><td align="center" rowspan="1" colspan="1">9 (20)</td></tr><tr><td align="right" rowspan="1" colspan="1">Diabetes mellitus (type I and II)</td><td align="center" rowspan="1" colspan="1">8 (17)</td><td align="center" rowspan="1" colspan="1">8 (17)</td></tr><tr><td align="right" rowspan="1" colspan="1">Blood pressure &#x02265; 130/80 mmHg</td><td align="center" rowspan="1" colspan="1">27 (56)</td><td align="center" rowspan="1" colspan="1">31 (67)</td></tr><tr><td align="left" rowspan="1" colspan="1">Main procedure during hospitalization, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">PCI with stent implantation</td><td align="center" rowspan="1" colspan="1">12 (25.0)</td><td align="center" rowspan="1" colspan="1">18 (39.1)</td></tr><tr><td align="right" rowspan="1" colspan="1">Coronary bypass</td><td align="center" rowspan="1" colspan="1">12 (25.0)</td><td align="center" rowspan="1" colspan="1">5 (10.9)</td></tr><tr><td align="right" rowspan="1" colspan="1">Medical therapy only</td><td align="center" rowspan="1" colspan="1">24 (50.0)</td><td align="center" rowspan="1" colspan="1">23 (50.0)</td></tr></tbody></table><table-wrap-foot><attrib>All P-values concerning differences between the two groups are &#x0003e; 0.05. Variables are given as geometric mean (percent of total participants of intervention/ control group) or mean &#x000b1; standard deviation (SD), BMI; body mass index, PCI; percutaneous coronary intervention</attrib></table-wrap-foot></table-wrap></sec><sec id="S16"><title>Adherence to MAT-CHDSP criteria</title><p>Overall adherence (adherence to all criteria) increased in both groups from baseline to 12 months, and was significantly higher in IG patients compared to CG patients at study end, p&#x0003c;0.001, see <xref ref-type="table" rid="T2">Table 2</xref>. This difference was mainly caused by the significant difference in adherence to the life-style criteria (no 19-21) in the MAT-CHDSP criteria (p&#x0003c;0.001).</p><table-wrap orientation="portrait" id="T2" position="float"><label>Table 2.</label><caption><p>Adherence to MAT-CHDSP criteria at baseline and 12 months after hospital discharge in the 48 intervention group patients (912 applicable criteria) and the 46 control group patients (874 applicable criteria)</p></caption><table frame="hsides" rules="groups" cellpadding="table" border="1" cellspacing="0" width="400pt"><thead><tr><th align="center" colspan="2" rowspan="2">Criterion focus<xref ref-type="fn" rid="t2n1">#</xref></th><th align="center" colspan="6" rowspan="1">Adherence Intervention group (IG)</th><th align="center" colspan="6" rowspan="1">Adherence Control group (CG)</th><th align="center" rowspan="3" colspan="1">p-value</th></tr><tr><th align="center" colspan="3" rowspan="1">Baseline</th><th align="center" colspan="3" rowspan="1">12 months</th><th align="center" colspan="3" rowspan="1">Baseline</th><th align="center" colspan="3" rowspan="1">12 months</th></tr><tr><th align="center" colspan="2" rowspan="1"><italic>In patients with established coronary heart disease</italic></th><th align="center" colspan="2" rowspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" colspan="2" rowspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" colspan="2" rowspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" colspan="2" rowspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Aspirin prescription</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>95,8</bold></td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>89,6</bold></td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>91,3</bold></td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>91,3</bold></td><td align="center" rowspan="1" colspan="1">0,011</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Clopidogrel prescription if contraindications/intolerance to aspirin</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">/0</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">/2</td><td align="center" rowspan="1" colspan="1"><bold>50,0</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">/2</td><td align="center" rowspan="1" colspan="1"><bold>50,0</bold></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">/1</td><td align="center" rowspan="1" colspan="1"><bold>0</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Clopidogrel prescription if MI or unstable AP, but no coronary stent implantation</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">/2</td><td align="center" rowspan="1" colspan="1"><bold>100</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">/1</td><td align="center" rowspan="1" colspan="1"><bold>100</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Clopidogrel prescription if PCI with stent implantation</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">/14</td><td align="center" rowspan="1" colspan="1"><bold>100</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">/20</td><td align="center" rowspan="1" colspan="1"><bold>100</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Statin prescription</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>97,9</bold></td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>95,8</bold></td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>91,3</bold></td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>95,7</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Total cholesterol &#x02264; 4.5 mmol/L and LDL cholesterol &#x02264; 2.5 mmol/L</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">/47</td><td align="center" rowspan="1" colspan="1"><bold>27,7</bold></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>27,1</bold></td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">/42</td><td align="center" rowspan="1" colspan="1"><bold>38,1</bold></td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">/45</td><td align="center" rowspan="1" colspan="1"><bold>42,2</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Therapy amendments<xref ref-type="fn" rid="t2n3"><sup>&#x000a7;</sup></xref> if unachieved therapy goals for cholesterol</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">/32</td><td align="center" rowspan="1" colspan="1"><bold>59,4</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">/25</td><td align="center" rowspan="1" colspan="1"><bold>60,0</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">&#x000df;-blocker prescription</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>72,9</bold></td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>62,5</bold></td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>82,6</bold></td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>80,4</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">SBP &#x02264; 130 mmHg and DBP &#x02264; 80 mmHg</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>35,4</bold></td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>41,7</bold></td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>34,8</bold></td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>41.3</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Therapy amendments<xref ref-type="fn" rid="t2n3"><sup>&#x000a7;</sup></xref> if unachieved therapy goals for SBP and DBP</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">/27</td><td align="center" rowspan="1" colspan="1"><bold>40,7</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">/31</td><td align="center" rowspan="1" colspan="1"><bold>41,9</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">ACE inhibitor or ARB prescription if LVSD (ejection fraction &#x0003c; 45 %)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">/12</td><td align="center" rowspan="1" colspan="1"><bold>100</bold></td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">/12</td><td align="center" rowspan="1" colspan="1"><bold>100</bold></td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">/9</td><td align="center" rowspan="1" colspan="1"><bold>77,8</bold></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">/9</td><td align="center" rowspan="1" colspan="1"><bold>88.9</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">ACE inhibitor or ARB prescription if DM with hypertension or nephropathy</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">/8</td><td align="center" rowspan="1" colspan="1"><bold>75,0</bold></td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">/8</td><td align="center" rowspan="1" colspan="1"><bold>87,5</bold></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">/8</td><td align="center" rowspan="1" colspan="1"><bold>50,0</bold></td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">/8</td><td align="center" rowspan="1" colspan="1"><bold>62,5</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">... documentation of blood glucose measurements &#x0003c; 7.0 mmol/L at hospital admission</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>68,8</bold></td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>83,3</bold></td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>71,7</bold></td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>87,0</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">... documentation of a new blood glucose and/or HbA1c measurement if first measurement &#x02265; 7.0 mmol/L</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">/16</td><td align="center" rowspan="1" colspan="1"><bold>43,8</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">/17</td><td align="center" rowspan="1" colspan="1"><bold>52,9</bold></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"><bold>-</bold></td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">... documentation of smoking cessation advice in smokers</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">/7</td><td align="center" rowspan="1" colspan="1"><bold>57,1</bold></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">/8</td><td align="center" rowspan="1" colspan="1"><bold>100</bold></td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">/11</td><td align="center" rowspan="1" colspan="1"><bold>54,5</bold></td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">/9</td><td align="center" rowspan="1" colspan="1"><bold>55.6</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">... documentation of weight, height, BMI and/or waist circumference</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>43,8</bold></td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>97,9</bold></td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>26,1</bold></td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>93.5</bold></td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">... documentation of weight reduction advice if overweight (BMI &#x02265; 30 kg/m2)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">/7</td><td align="center" rowspan="1" colspan="1"><bold>28,6</bold></td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">/11</td><td align="center" rowspan="1" colspan="1"><bold>90,9</bold></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">/4</td><td align="center" rowspan="1" colspan="1"><bold>0</bold></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">/13</td><td align="center" rowspan="1" colspan="1"><bold>0</bold></td><td align="center" rowspan="1" colspan="1">&#x0003c; 0,001</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">... documentation of dietary advice</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>8,3</bold></td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>97,9</bold></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>17,4</bold></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>17.4</bold></td><td align="center" rowspan="1" colspan="1">&#x0003c; 0,001</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">... documentation of physical activity advice</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>12,5</bold></td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">/48</td><td align="center" rowspan="1" colspan="1"><bold>97,9</bold></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>23,9</bold></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">/46</td><td align="center" rowspan="1" colspan="1"><bold>23.9</bold></td><td align="center" rowspan="1" colspan="1">&#x0003c; 0,001</td></tr><tr><td align="center" colspan="2" rowspan="1">Overall</td><td align="center" rowspan="1" colspan="1">299</td><td align="center" rowspan="1" colspan="1">/556</td><td align="center" rowspan="1" colspan="1"><bold>53,8</bold></td><td align="center" rowspan="1" colspan="1">371</td><td align="center" rowspan="1" colspan="1">/473</td><td align="center" rowspan="1" colspan="1"><bold>78,4</bold></td><td align="center" rowspan="1" colspan="1">294</td><td align="center" rowspan="1" colspan="1">/538</td><td align="center" rowspan="1" colspan="1"><bold>54,6</bold></td><td align="center" rowspan="1" colspan="1">281</td><td align="center" rowspan="1" colspan="1">/453</td><td align="center" rowspan="1" colspan="1"><bold>62,0</bold></td><td align="center" rowspan="1" colspan="1">&#x0003c; 0,001</td></tr></tbody></table><table-wrap-foot><fn id="t2n1"><label>#</label><p>Criteria 6 and 14 were omitted.</p></fn><fn id="t2n2"><label>&#x000a4;</label><p>Adherence is calculated as the number of criteria where the standard can be answered &#x02018;YES&#x02019; divided by the number of applicable criteria, i.e. where the standard is answered YES, NO, NO-justified or where information to answer the standard is insufficient.</p></fn><fn id="t2n3"><label>&#x000a7;</label><p>Increased dose, change of drug and/or addition of drug.</p></fn><fn id="t2n4"><label>*</label><p>P-values reflect both change from baseline to study end as well as difference in between groups at study end.ACE, angiotensin converting enzyme; AP, angina pectoris; ARB, angiotensin II receptor blocker; BMI, body mass index; CI, Confidence interval; DM, diabetes mellitus; DPB, diastolic blood pressure; LDL, low-density lipoprotein; LVSD, left ventricular systolic dysfunction; NS, Not significant; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.</p></fn></table-wrap-foot></table-wrap><p>Prescription of antiplatelet medications was high both at baseline and at 12 months, see criteria 1-4 in <xref ref-type="table" rid="T2">Table 2</xref>. All cases of non-adherence to aspirin prescribing among IG patients at 12 months were justified; this was not the case in the three CG patients. More than 90% of patients in both groups were prescribed a statin at baseline and at 12 months, see criterion 5 in <xref ref-type="table" rid="T2">Table 2</xref>. At 12 months, the two IG patients not prescribed a statin had a justified reason, which was not the case for the two CG patients not prescribed a statin. At baseline, a &#x003b2;-blocker was prescribed in &#x0003e;70% of patients in both groups, see criterion 9 in <xref ref-type="table" rid="T2">Table 2</xref>. From baseline to 12 months, adherence decreased by respectively 10.4% and 2.2% in IG and CG patients. This decrease was justified in IG patients, but not in CG patients. In both IG and CG patients, prescription of an angiotensin-converting enzyme (ACE)-inhibitor or an angiotensin receptor II blocker (ARB) was higher in eligible patients with left systolic ventricular dysfunction (LSVD) compared to eligible patients with diabetes mellitus (criterion 12 and 13 in <xref ref-type="table" rid="T2">Table 2</xref>). More eligible IG patients with diabetes mellitus type 2 were prescribed and ACE-inhibitor or an ARB at 12 months compared to baseline. This difference was not significant.</p><p>Therapy goal achievement for total and LDL cholesterol and BP was relatively low at baseline, and it did not increase significantly in any groups from baseline to 12 months (criterion 7 and 10, <xref ref-type="table" rid="T2">Table 2</xref>). In patients with unachieved therapy goals for cholesterol and BP at baseline, about 40-50% of the patients in both groups were discharged without any therapy amendment or instructions to the next caregiver in order to achieve therapy goals (criteria 8 and 11, <xref ref-type="table" rid="T2">Table 2</xref>). About 50% of patients with blood glucose &#x0003e;7 mmol/L at hospital admittance were discharged without a second measurement of blood glucose or HbA1c (criterion 16, <xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec id="S17"><title>Applicability</title><p>For both study groups, insufficient data to decide whether the qualifying statement was applicable (IDq) mostly affected baseline applications of criterion 19 due to lack of information on body weight and height or BMI. This was less prominent at 12 months. Applicability decreased from 61% at baseline to 51% at study end in both groups. This was because criteria 8, 11 and 16 could not be applied at study end, as they are designed for application after e.g. a hospital stay, to identify whether medication amendments have been appropriately conducted. More details on applicability, justified non-adherence and insufficient data can be retrieved by contacting the authors.</p></sec><sec id="S18"><title>Biomedical risk factors and therapy goal achievement</title><p>No intervention approach or data collection instrument presented any major difficulties during the study. Biomedical measures at baseline and at study end did not differ significantly between the groups (p&#x0003e;0.05), see <xref ref-type="table" rid="T3">Table 3</xref>. No improvements in biomedical measures from baseline to study end were observed for IG patients, but a significant improvement in LDL cholesterol was observed for CG patients (p=0.009), see <xref ref-type="table" rid="T3">Table 3</xref>. Even though no significant improvement in BP was observed in any group, three more patients in both groups had achieved their BP therapy goals at study end compared to baseline, see criterion 10, <xref ref-type="table" rid="T3">Table 3</xref>.</p><table-wrap orientation="portrait" id="T3" position="float"><label>Table 3.</label><caption><p>Biomedical values for the intervention group (n = 48) and the control group (n = 46) throughout the study</p></caption><table frame="hsides" rules="groups" cellpadding="table" border="1" cellspacing="0" width="400pt"><thead><tr><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="6" rowspan="1">Intervention group</th><th align="center" colspan="4" rowspan="1">Control group</th></tr><tr><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">3 months</th><th align="center" colspan="2" rowspan="1">12 months</th><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">12 months</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">(1.14)</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">(0.87)</td><td align="center" rowspan="1" colspan="1">2,8</td><td align="center" rowspan="1" colspan="1">(0.94)</td><td align="center" rowspan="1" colspan="1"><italic>3.1</italic></td><td align="center" rowspan="1" colspan="1"><italic>(1.20)</italic></td><td align="center" rowspan="1" colspan="1"><italic>2.5</italic></td><td align="center" rowspan="1" colspan="1"><italic>(0.81)</italic></td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">5.8</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">5.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">(1.28)</td><td align="center" rowspan="1" colspan="1">4.7</td><td align="center" rowspan="1" colspan="1">(1.06)</td><td align="center" rowspan="1" colspan="1">4.8</td><td align="center" rowspan="1" colspan="1">(1.12)</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">(1.40)</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">(0.91)</td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">8.2</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">7.3</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">8.5</td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">8.0</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">7.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose, (mmol/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1">(2.89)</td><td align="center" rowspan="1" colspan="1">6.2</td><td align="center" rowspan="1" colspan="1">(2.46)</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">(2.36)</td><td align="center" rowspan="1" colspan="1">7.5</td><td align="center" rowspan="1" colspan="1">(3.54)</td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">(3.6)</td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max value</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">15.6</td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">15.5</td><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">20.0</td><td align="center" rowspan="1" colspan="1">3.9</td><td align="center" rowspan="1" colspan="1">23.5</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">(1.04)</td><td align="center" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1">(0.99)</td><td align="center" rowspan="1" colspan="1">6.2</td><td align="center" rowspan="1" colspan="1">(0.99)</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">(1.35)</td><td align="center" rowspan="1" colspan="1">6.2</td><td align="center" rowspan="1" colspan="1">(0.93)</td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">8.6</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">9.9</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">10.4</td><td align="center" rowspan="1" colspan="1">5.4</td><td align="center" rowspan="1" colspan="1">9.7</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">9.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">134.0</td><td align="center" rowspan="1" colspan="1">(18.9)</td><td align="center" rowspan="1" colspan="1">135.1</td><td align="center" rowspan="1" colspan="1">(19.2)</td><td align="center" rowspan="1" colspan="1">135.2</td><td align="center" rowspan="1" colspan="1">(19.3)</td><td align="center" rowspan="1" colspan="1">141.9</td><td align="center" rowspan="1" colspan="1">(20.9)</td><td align="center" rowspan="1" colspan="1">135.4</td><td align="center" rowspan="1" colspan="1">(19.8)</td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">178</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">177</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">197</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">188</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">178</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Mean (SD)</td><td align="center" rowspan="1" colspan="1">79.2</td><td align="center" rowspan="1" colspan="1">(10.5)</td><td align="center" rowspan="1" colspan="1">79.3</td><td align="center" rowspan="1" colspan="1">(12.2)</td><td align="center" rowspan="1" colspan="1">77.2</td><td align="center" rowspan="1" colspan="1">(10.1)</td><td align="center" rowspan="1" colspan="1">79.2</td><td align="center" rowspan="1" colspan="1">(11.9)</td><td align="center" rowspan="1" colspan="1">77.7</td><td align="center" rowspan="1" colspan="1">(10.3)</td></tr><tr><td align="right" rowspan="1" colspan="1">Min, max</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">105</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">96</td></tr></tbody></table><table-wrap-foot><attrib>All P-values concerning differences in between groups at baseline and from baseline to 12 months are &#x0003e; 0.05, except the P-value for the difference between mean baseline values and mean 12 month values for low-density-lipoprotein (LDL) cholesterol in the control group, where P = 0.009 (italic). Variables are given as geometric mean (percent of total participants of intervention/ control group) or mean &#x000b1; standard deviation (SD); LDL, Low-density lipoprotein; HbA1c, glycosylated haemoglobin.</attrib></table-wrap-foot></table-wrap></sec><sec id="S19"><title>Reliability of MAT-CHDSP application</title><p>Inter-observer agreement tests on 12 months data showed excellent reproducibility of MAT-CHDSP application with a &#x00138;-value of 0.91 (95 % CI; 0.89, 0.94).<xref rid="B26" ref-type="bibr">26</xref></p></sec></sec><sec sec-type="discussion" id="S20"><title>DISCUSSION</title><p>We have developed a pharmacist-led follow-up program for post-discharged patients with
established CHD proved functional, both clinically and logistically. To our knowledge, no similar
program has been described in the literature. The low lost-to-follow-up rate in addition to a high
satisfaction identified by qualitative interviews, indicates that the intervention was appreciated
by the patients.<xref rid="B27" ref-type="bibr">27</xref> High patient satisfaction has also been
shown by others studying patient satisfaction with pharmaceutical care.<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref></p><p>We found that overall adherence to guideline recommendations defined in the MAT-CHDSP increased in both groups. This indicates that focus on guideline adherence in itself may increase adherence and consequently improve therapy. Our study shows that this can be a pharmacist task. Although no significant increase in biomedical measures could be observed in favour of IG patients, we identified a higher documentation of justified reasons for non-prescription of guideline recommended medications aspirin, statins and beta-blockers in IG patients compared to CG patients at study end. At study end, we also observed higher prescription of ACE-inhibitors or ARBs in eligible IG patients with diabetes mellitus type 2 compared to CG patients at study end. Due to small numbers, these differences were not statistical significant, but indicates that the MATCHDSP can function as a follow-up tool to be applied in clinical practice. It also underlines the clinical pharmacist&#x02019;s impact on documentation, which is essential in health care.</p><p>A high prescription rate of guideline recommended medications was observed in both groups at
baseline and study end, which is higher than observed in other studies.<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>
Achievement of therapy goals was low in both study groups, which clearly supports findings from
other studies arguing for introducing successful interventions to improve patient care for these
patients.<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref> Other studies have shown that the
clinical pharmacist can have a significant positive impact in direct care for CHD patients, both
concerning lipid- and BP management, appropriate prescribing, smoking cessation and guideline
adherence.<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref></p><p>There are two major limitations of this study. First, the study was underpowered to detect potential differences between the study groups. We based our sample size calculations on a low adherence for BP therapy goal achievement of 20%, but the initial adherence in our study was higher. In addition, the adherence increase throughout the study was similar in both study groups. The lost-to follow-up rate was low, but did not compensate for this. Second, the MAT-CHDSP may be unsuitable to measure change in actual care. It is possible that the major sources of improvements were in the documentation of care, not the provision of care. This may again explain the apparent lack of beneficial clinical effects from the follow-up program. Additionally, the impact of lifestyle advices depend on several factors, such as the quality of the advices, the patient&#x02019;s ability to understand the information, and patient adherence. It is necessary to control these factors in order to decide on the influence of lifestyle counselling on the biomedical outcomes.</p><p>Other elements that may have contributed to the inability to demonstrate a benefit in favour of the intervention group include the following: First, prescription rates (i.e. adherence to criteria 1-5, 9, 12 and 13) were high in both groups at baseline, and consequently, the opportunity to increase appropriate prescribing was low. Second, selection bias may have been introduced by the voluntarily study participation. The randomization process was successful, resulting in comparable study groups, but the included patients may be different from those who refused participation. Also, our study population was recruited as they were hospitalized due to a coronary event, for which the severity of the event itself may have had an impact on medication adherence and lifestyle. This may have diluted a potential effect of the intervention. Third, Hawthorn effects may have led to improvements in adherence and biomedical measures among CG patients that would not have been seen outside the study. This may consequently have diluted any effect that could have been attributable to the intervention.<xref rid="B37" ref-type="bibr">37</xref> This is supported by the fact that CG patients expressed disappointment after the randomization process. In addition, clinicians and GPs were aware of the study and may have changed behaviour. However, this is not supported by the low therapy goal achievement at study end. Fourth, GPs were sometimes reluctant to make changes concerning medications initiated at the hospital, and hence did not always effectuate recommendations from the clinical pharmacist. This is not a new dilemma, and it has been shown that the GPs consider it inappropriate to take responsibility for the patients in about 50% of all discharges.<xref rid="B38" ref-type="bibr">38</xref> Unfortunately, we were do not have reliable measures on the proportion of recommendations that were actually accepted by the GPs, as we were relying on patient information during follow-up. Pharmacist prescriptive authority, which is routine in the UK and US, may have counteracted this.<xref rid="B39" ref-type="bibr">39</xref></p><p>In order to explore a possible benefit of the follow-up program, a larger study is necessary. In addition, we suggest the following improvements of the program itself:</p><p>
<list list-type="order"><list-item><p>A closer collaboration with the prescriber to facilitate discussions and effectuate recommendations more rapidly. This has been described as a key feature in similar programs (13). In hospitals, this may be feasible if the clinical pharmacist is part of the ambulatory follow-up team. In primary care, a &#x02019;hot line&#x02019; to the GP&#x02019;s office could be established, or the clinical pharmacist could be situated at the GP&#x02019;s office.</p></list-item><list-item><p>Conduct the first medication reconciliation and medication therapy reviews before hospital discharge, including appropriate approaches to solve drug-related problems, make medication amendments and communicate amendments to the next care level. This may counteract the GPs&#x02019; resistance to amending medications initiated at the hospital,</p></list-item><list-item><p>Prescriptive authority for the clinical pharmacist according to agreed algorithms may facilitate dose titration and therapy goal achievement. This could reduce the number of extra appointments with the GP and be economically favourable.</p></list-item><list-item><p>More frequent follow-up meetings initially may facilitate a more aggressive medication titration and rapid achievement of therapy goals. In the Euro Action program, patients met every week during the sixteen-week program, and also attended group workshops and a supervised exercise class.<xref rid="B40" ref-type="bibr">40</xref></p></list-item></list>
</p></sec><sec sec-type="conclusions" id="S21"><title>CONCLUSIONS</title><p>This is to our knowledge the first description of a twelve-month lasting follow-up program for post-discharged patients with CHD led by a clinical pharmacist. The program was successful concerning logistics and patient experiences. In both study groups at baseline, we observed a high prescription proportion of guideline recommended medications, a relatively low achievement of therapy goals, and an inadequate follow-up on unachieved therapy goals. During the study period, adherence to review criteria defined in the MAT-CHDSP increased in both groups. Even though no significant improvement of biomedical measures was observed in favor of the intervention group, the increased focus on adherence to guideline recommendations improved adherence to the MATCHDSP for both groups. This may in itself be an argument for such a follow-up program. Even though not significant, our study indicates that the clinical pharmacist may increase documentation of justified reasons non-prescription of guideline-recommended medications as well as increase appropriate prescription of ACE inhibitors and ARBs in eligible patients with diabetes mellitus type II. A larger, adequately powered study is warranted to explore the full benefit of the follow-up program. In addition, adjustments to the program, including a closer collaboration with the prescriber, is crucial.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>Thanks to participating patients and staff at the Department of Cardiology at the University Hospital of North-Norway (UNN). Thanks to the Northern Norway Regional Health Authority for funding laboratory expenses.</p></ack><fn-group><fn fn-type="conflict"><p><bold>CONFLICT OF INTEREST</bold></p><p>The authors declare that they have no conflicts of interest to disclose.</p><p>Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The laboratory expenses were covered by the Northern Norway Regional Health Authority.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>J</given-names></name><name><surname>Mensah</surname><given-names>G</given-names></name></person-group><source>Atlas of Heart Disease and Stroke</source><publisher-loc>Geneve</publisher-loc><publisher-name>WHO</publisher-name><year>2004</year><comment>ISBN:9789241562768</comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="web"><article-title>Causes of deaths</article-title><year>2010</year><source>Statistisk sentralbyr&#x000e5; (Eng: Statistics Norway)</source><date-in-citation>accessed 2010 Jul 13</date-in-citation><comment>Available from: URL: <uri xlink:href="http://www.ssb.no">http://www.ssb.no</uri></comment></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="web"><source>Scottish Intercollegate Guideline Network</source><date-in-citation>accessed 2010 Jul 13</date-in-citation><comment>Available from: URL: <uri xlink:href="http://www.sign.ac.uk/">http://www.sign.ac.uk/</uri></comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="web"><article-title>National Institute of Health and Clinical Excellence</article-title><date-in-citation>accessed 2010 Jul 13</date-in-citation><comment>Available from: URL: <uri xlink:href="http://www.nice.org.uk/">http://www.nice.org.uk/</uri></comment></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="web"><article-title>Nice Cardiovascular guidance. National Institute of Clinical Expertice (NICE)</article-title><year>2011</year><date-in-citation>accessed 2010 Jul 13</date-in-citation><comment>Available from: URL: <uri xlink:href="http://guidance.nice.org.uk/Topic/Cardiovascular">http://guidance.nice.org.uk/Topic/Cardiovascular</uri></comment></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horning</surname><given-names>KK</given-names></name><name><surname>Hoehns</surname><given-names>JD</given-names></name><name><surname>Doucette</surname><given-names>WR</given-names></name></person-group><article-title>Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review</article-title><source>J Manag Care Pharm</source><year>2007</year><volume>13</volume><issue>1</issue><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">17269834</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libungan</surname><given-names>B</given-names></name><name><surname>Stensdotter</surname><given-names>L</given-names></name><name><surname>Hjalmarson</surname><given-names>A</given-names></name><name><surname>From Attebring</surname><given-names>M</given-names></name><name><surname>Lindqvist</surname><given-names>J</given-names></name><name><surname>B&#x000e4;ck</surname><given-names>M</given-names></name><name><surname>Herlitz</surname><given-names>J</given-names></name></person-group><article-title>Secondary prevention in coronary artery disease. Achieved goals and possibilities for improvements</article-title><source>Int J Cardiol</source><year>2012</year><volume>161</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage><comment>doi:10.1016/j.ijcard.2011.04.025</comment><pub-id pub-id-type="pmid">21601296</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Py&#x000f6;r&#x000e4;l&#x000e4;</surname><given-names>K</given-names></name><name><surname>Keil</surname><given-names>U</given-names></name></person-group><collab>EUROASPIRE Study Group</collab><article-title>EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2009</year><volume>16</volume><issue>2</issue><fpage>121</fpage><lpage>137</lpage><comment>doi:10.1097/HJR.0b013e3283294b1d</comment><pub-id pub-id-type="pmid">19287307</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coma-Canella</surname><given-names>I</given-names></name></person-group><article-title>[Relationship between mortality due to acute myocardial infarction and adherence to clinical guidelines]</article-title><source>Rev Esp Cardiol</source><year>2006</year><volume>59</volume><issue>3</issue><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">16712740</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>N</given-names></name></person-group><article-title>Improving medication adherence in chronic cardiovascular disease</article-title><source>Crit Care Nurse</source><year>2008</year><volume>28</volume><issue>5</issue><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">18827087</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nkansah</surname><given-names>N</given-names></name><name><surname>Mostovetsky</surname><given-names>O</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Chheng</surname><given-names>T</given-names></name><name><surname>Beney</surname><given-names>J</given-names></name><name><surname>Bond</surname><given-names>CM</given-names></name><name><surname>Bero</surname><given-names>L</given-names></name></person-group><article-title>Effect of outpatient pharmacists&#x02019; non-dispensing roles on patient outcomes and
prescribing patterns</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><volume>7</volume><elocation-id>575</elocation-id><comment>doi:10.1002/14651858.CD000336.pub2</comment></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Grace</surname><given-names>KA</given-names></name><name><surname>Taylor</surname><given-names>AJ</given-names></name></person-group><article-title>Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial</article-title><source>JAMA</source><year>2006</year><volume>296</volume><issue>21</issue><fpage>2563</fpage><lpage>2571</lpage><pub-id pub-id-type="pmid">17101639</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taveira</surname><given-names>TH</given-names></name><name><surname>Wu</surname><given-names>WC</given-names></name><name><surname>Martin</surname><given-names>OJ</given-names></name><name><surname>Schleinitz</surname><given-names>MD</given-names></name><name><surname>Friedmann</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>SC</given-names></name></person-group><article-title>Pharmacist-led cardiac risk reduction model</article-title><source>Prev Cardiol</source><year>2006</year><volume>9</volume><issue>4</issue><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">17085982</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>V</given-names></name><name><surname>Cavanagh</surname><given-names>M</given-names></name></person-group><article-title>The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist</article-title><source>Pharm World Sci</source><year>2003</year><volume>25</volume><issue>6</issue><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">14689819</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>LM</given-names></name></person-group><article-title>Twenty Years of Pharmacuetical Care Practice: What Have We Learned? Lecture held on June 6</article-title><year>2011</year><publisher-loc>Reykjavik, Iceland</publisher-loc></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>G</given-names></name></person-group><collab>EUROASPIRE II Study Group</collab><article-title>Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II</article-title><source>Atheroscler Suppl</source><year>2002</year><month>4</month><volume>2</volume><issue>4</issue><fpage>13</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11976072</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="web"><article-title>EuroAction - Demonstration Project in Preventive Cardiology</article-title><date-in-citation>accessed November 7 2011</date-in-citation><comment><uri xlink:href="http://www.escardio.org/Policy/Pages/EuroAction.aspx">http://www.escardio.org/Policy/Pages/EuroAction.aspx</uri></comment></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>BH</given-names></name><name><surname>Utnes</surname><given-names>J</given-names></name><name><surname>Naalsund</surname><given-names>L</given-names></name><name><surname>Giverhaug</surname><given-names>T</given-names></name></person-group><article-title>MAT-CHDSP, a novel medication assessment tool for evaluation of secondary prevention of coronary heart disease</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2011</year><volume>20</volume><issue>3</issue><fpage>249</fpage><lpage>257</lpage><comment>doi:10.1002/pds.2054</comment><pub-id pub-id-type="pmid">21351306</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>BH</given-names></name><name><surname>Smabrekke</surname><given-names>L</given-names></name><name><surname>Trovik</surname><given-names>T</given-names></name><name><surname>Giverhaug</surname><given-names>T</given-names></name></person-group><article-title>Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention</article-title><source>Eur J Clin Pharmacol</source><year>2013</year><volume>69</volume><issue>3</issue><fpage>703</fpage><lpage>709</lpage><comment>doi:10.1007/s00228-012-1402-7</comment><pub-id pub-id-type="pmid">22990329</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="web"><article-title>Kommuner og befolkning pr. helseforetak [Communities and inhabitants for each Health Trust]</article-title><date-in-citation>accessed 2010 Jul 13</date-in-citation><comment>Available from: URL:
<uri xlink:href="http://www.helse-nord.no/befolkning-pr-helseforetak/category22368.html">http://www.helse-nord.no/befolkning-pr-helseforetak/category22368.html</uri></comment></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>B&#x000f8;naa</surname><given-names>K</given-names></name></person-group><article-title>Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis (NORSTENT)</article-title><source>Clinicaltrials gov</source><year>2011</year><month>5</month><day>19</day><date-in-citation>accessed November 7 2011</date-in-citation><comment>Available from: URL: <uri xlink:href="http://clinicaltrials.gov/ct2/show/NCT00811772">http://clinicaltrials.gov/ct2/show/NCT00811772</uri></comment></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="web"><article-title>Randomisation at the Norwegian University of Science and Technology</article-title><date-in-citation>accessed November 7 2011</date-in-citation><comment><uri xlink:href="http://www.ntnu.edu/dmf/akf/randomisering">http://www.ntnu.edu/dmf/akf/randomisering</uri></comment></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rollnick</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>WR</given-names></name><name><surname>Butler</surname><given-names>CC</given-names></name></person-group><source>Motivational interviewing in health care</source><publisher-loc>New York</publisher-loc><publisher-name>The Guilford Press</publisher-name><year>2008</year></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="web"><article-title>Validated Blood Pressure Monitors by British Hypertension Society</article-title><date-in-citation>accessed November 7 2011</date-in-citation><comment><uri xlink:href="http://www.bhsoc.org/bloodpressurelist.stm">http://www.bhsoc.org/blood pressure list.stm</uri></comment></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Germano</surname><given-names>G</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Heagerty</surname><given-names>AM</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Narkiewicz</surname><given-names>K</given-names></name><name><surname>Ruilope</surname><given-names>L</given-names></name><name><surname>Rynkiewicz</surname><given-names>A</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name><name><surname>Struijker</surname><given-names>Boudier HA</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Camm</surname><given-names>J</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Dean</surname><given-names>V</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Funck-Brentano</surname><given-names>C</given-names></name><name><surname>Hellemans</surname><given-names>I</given-names></name><name><surname>Kristensen</surname><given-names>SD</given-names></name><name><surname>McGregor</surname><given-names>K</given-names></name><name><surname>Sechtem</surname><given-names>U</given-names></name><name><surname>Silber</surname><given-names>S</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Widimsky</surname><given-names>P</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Erdine</surname><given-names>S</given-names></name><name><surname>Narkiewicz</surname><given-names>K</given-names></name><name><surname>Kiowski</surname><given-names>W</given-names></name><name><surname>Agabiti-Rosei</surname><given-names>E</given-names></name><name><surname>Ambrosioni</surname><given-names>E</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Heagerty</surname><given-names>AM</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Lindholm</surname><given-names>LH</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Manolis</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>PM</given-names></name><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name><name><surname>Struijker-Boudier</surname><given-names>HA</given-names></name><name><surname>Viigimaa</surname><given-names>M</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Agabiti-Rosei</surname><given-names>E</given-names></name><name><surname>Ambrosioni</surname><given-names>E</given-names></name><name><surname>Bertomeu</surname><given-names>V</given-names></name><name><surname>Clement</surname><given-names>D</given-names></name><name><surname>Erdine</surname><given-names>S</given-names></name><name><surname>Farsang</surname><given-names>C</given-names></name><name><surname>Gaita</surname><given-names>D</given-names></name><name><surname>Kiowski</surname><given-names>W</given-names></name><name><surname>Lip</surname><given-names>G</given-names></name><name><surname>Mallion</surname><given-names>JM</given-names></name><name><surname>Manolis</surname><given-names>AJ</given-names></name><name><surname>Nilsson</surname><given-names>PM</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>E</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Tamargo</surname><given-names>J</given-names></name><name><surname>van Zwieten</surname><given-names>P</given-names></name><name><surname>Viigimaa</surname><given-names>M</given-names></name><name><surname>Waeber</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name></person-group><collab>The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology</collab><article-title>2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>12</issue><fpage>1462</fpage><lpage>1536</lpage><pub-id pub-id-type="pmid">17562668</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>C</given-names></name></person-group><article-title>Real world research</article-title><source>A resource for social scientists and practitioner-researchers</source><edition>2nd ed</edition><publisher-loc>Malden</publisher-loc><publisher-name>Blackwell</publisher-name><year>2002</year></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>BH</given-names></name><name><surname>Storli</surname><given-names>SL</given-names></name><name><surname>Smabrekke</surname><given-names>L</given-names></name></person-group><article-title>A pharmacist-led follow-up program for patients with coronary heart disease in North
Norway--a qualitative study exploring patient experiences</article-title><source>BMC Res Notes</source><year>2014</year><volume>7</volume><elocation-id>575</elocation-id><comment>doi:10.1186/1756-05007-197</comment><pub-id pub-id-type="pmid">25164127</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalonde</surname><given-names>L</given-names></name><name><surname>Hudon</surname><given-names>E</given-names></name><name><surname>Goudreau</surname><given-names>J</given-names></name><name><surname>B&#x000e9;langer</surname><given-names>D</given-names></name><name><surname>Villeneuve</surname><given-names>J</given-names></name><name><surname>Perreault</surname><given-names>S</given-names></name><name><surname>Blais</surname><given-names>L</given-names></name><name><surname>Lamarre</surname><given-names>D</given-names></name></person-group><article-title>Physician-pharmacist collaborative care in dyslipidemia management: The perception of clinicians and patients</article-title><source>Res Social Adm Pharm</source><year>2011</year><volume>7</volume><issue>3</issue><fpage>233</fpage><lpage>245</lpage><comment>doi:10.1016/j.sapharm.2010.05.003</comment><pub-id pub-id-type="pmid">21272548</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalho de</surname><given-names>Oliveira D</given-names></name><name><surname>Brummel</surname><given-names>AR</given-names></name><name><surname>Miller</surname><given-names>DB</given-names></name></person-group><article-title>Medication therapy management:10 years of experience in a large integrated health care system</article-title><source>J Manag Care Pharm</source><year>2010</year><volume>16</volume><issue>3</issue><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">20331323</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>A</given-names></name><name><surname>Crump</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>M</given-names></name></person-group><article-title>Collaborative prescribing: A qualitative exploration of a role for pharmacists in mental health</article-title><source>Res Social Adm Pharm</source><year>2012</year><volume>8</volume><issue>3</issue><fpage>179</fpage><lpage>192</lpage><comment>doi:10.1016/j.sapharm.2011.04.003</comment><pub-id pub-id-type="pmid">21831724</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Till</surname><given-names>LT</given-names></name><name><surname>Voris</surname><given-names>JC</given-names></name><name><surname>Horst</surname><given-names>JB</given-names></name></person-group><article-title>Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting</article-title><source>J Manag Care Pharm</source><year>2003</year><volume>9</volume><issue>3</issue><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">14613471</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neto</surname><given-names>PR</given-names></name><name><surname>Marusic</surname><given-names>S</given-names></name><name><surname>de Lyra</surname><given-names>DP</given-names><suffix>J&#x000fa;nior</suffix></name><name><surname>Pilger</surname><given-names>D</given-names></name><name><surname>Cruciol-Souza</surname><given-names>JM</given-names></name><name><surname>Gaeti</surname><given-names>WP</given-names></name><name><surname>Cuman</surname><given-names>RK</given-names></name></person-group><article-title>Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients</article-title><source>J Pharm Pharm Sci</source><year>2011</year><volume>14</volume><issue>2</issue><fpage>249</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">21733413</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Ockene</surname><given-names>IS</given-names></name><name><surname>Rosal</surname><given-names>MC</given-names></name><name><surname>Merriam</surname><given-names>PA</given-names></name><name><surname>Ockene</surname><given-names>JK</given-names></name><name><surname>Gandhi</surname><given-names>PJ</given-names></name></person-group><article-title>Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease</article-title><source>Cholesterol</source><year>2010</year><volume>2010</volume><fpage>383281</fpage><comment>doi:10.1155/2010/383281</comment><pub-id pub-id-type="pmid">21490915</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axtell</surname><given-names>SS</given-names></name><name><surname>Ludwig</surname><given-names>E</given-names></name><name><surname>Lope-Candales</surname><given-names>P</given-names></name></person-group><article-title>Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction</article-title><source>Clin Cardiol</source><year>2001</year><volume>24</volume><issue>2</issue><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">11214740</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>TC</given-names></name><name><surname>Noirot</surname><given-names>LA</given-names></name><name><surname>Blickensderfer</surname><given-names>A</given-names></name><name><surname>Rachmiel</surname><given-names>E</given-names></name><name><surname>Schaiff</surname><given-names>R</given-names></name><name><surname>Kessels</surname><given-names>A</given-names></name><name><surname>Braverman</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name><name><surname>Waterman</surname><given-names>B</given-names></name><name><surname>Dunagan</surname><given-names>WC</given-names></name></person-group><article-title>An intervention to improve secondary prevention of coronary heart disease</article-title><source>Arch Intern Med</source><year>2007</year><volume>167</volume><issue>6</issue><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">17389290</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>NR</given-names></name><name><surname>Fotis</surname><given-names>MA</given-names></name><name><surname>Yarnold</surname><given-names>PR</given-names></name><name><surname>Gheorghiade</surname><given-names>M</given-names></name></person-group><article-title>Pharmacist interventions to improve the management of coronary artery disease</article-title><source>Am J Health Syst Pharm</source><year>2004</year><volume>61</volume><issue>24</issue><fpage>2672</fpage><lpage>2678</lpage><pub-id pub-id-type="pmid">15646702</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="web"><article-title>Hawthorn effect</article-title><date-in-citation>accessed November 7, 2011</date-in-citation><comment><uri xlink:href="http://www.merriam-webster.com/dictionary/hawthorne%20effect">http://www.merriam-webster.com/dictionary/hawthorne%20effect</uri></comment></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeve</surname><given-names>H</given-names></name><name><surname>Baxter</surname><given-names>K</given-names></name><name><surname>Newton</surname><given-names>P</given-names></name><name><surname>Burkey</surname><given-names>Y</given-names></name><name><surname>Black</surname><given-names>M</given-names></name><name><surname>Roland</surname><given-names>M</given-names></name></person-group><article-title>Long-term follow-up in outpatient clinics. 1: The view from general practice</article-title><source>Fam Pract</source><year>1997</year><volume>14</volume><issue>1</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">9061340</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geber</surname><given-names>J</given-names></name><name><surname>Parra</surname><given-names>D</given-names></name><name><surname>Beckey</surname><given-names>NP</given-names></name><name><surname>Korman</surname><given-names>L</given-names></name></person-group><article-title>Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting</article-title><source>Pharmacotherapy</source><year>2002</year><volume>22</volume><issue>6</issue><fpage>738</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">12066964</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>DA</given-names></name><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>Connolly</surname><given-names>S</given-names></name><name><surname>Jennings</surname><given-names>C</given-names></name><name><surname>Mead</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Holden</surname><given-names>A</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Collier</surname><given-names>T</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Faergeman</surname><given-names>O</given-names></name></person-group><collab>EUROACTION Study Group</collab><article-title>Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial</article-title><source>Lancet</source><year>2008</year><volume>371</volume><issue>9629</issue><fpage>1999</fpage><lpage>2012</lpage><comment>doi:10.1016/S0140-6736(08)60868-5</comment><pub-id pub-id-type="pmid">18555911</pub-id></element-citation></ref></ref-list></back></article>